Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program
Fátima Cardoso(Breast Cancer Alliance), Sharon H. Giordano(The University of Texas MD Anderson Cancer Center), Joanna Vermeij(Ziekenhuisnetwerk Antwerpen Stuivenberg), Kim Benstead(Cheltenham General Hospital), Theodora Goulioti(Champalimaud Foundation), Kevin Punie(KU Leuven), Ingrid Hedenfalk(Lund University), Kathryn J. Ruddy(Mayo Clinic in Arizona), Monika Nowaczyk, Melissa P. Murray(Memorial Sloan Kettering Cancer Center), Elise van Leeuwen-Stok, Isabel T. Rubio(Clinica Universidad de Navarra), Larissa A. Korde(National Cancer Institute), Carolien H. M. van Deurzen(Erasmus MC), Stefan Aebi(University of Lucerne), K.C. Aalders(European Organisation for Research and Treatment of Cancer), Clifford A. Hudis(American Society of Clinical Oncology), Aleksandra Peric(European Organisation for Research and Treatment of Cancer), Lavinia P. Middleton(The University of Texas MD Anderson Cancer Center), Leen Slaets(European Organisation for Research and Treatment of Cancer), Barbro Linderholm(Karolinska University Hospital), Jane Bayani(Ontario Institute for Cancer Research), John W.M. Martens(Erasmus MC), Eric P. Winer(University of Vermont), Catherine M. Kelly(Cancer Trials Ireland), Judith Fraser(Beatson West of Scotland Cancer Centre), Saskia Litière(European Organisation for Research and Treatment of Cancer), John M.S. Bartlett(Edinburgh Cancer Research), Peggy L. Porter(Seattle University), C.P. Schröder(University Medical Center Groningen), Cecilia Nilsson(Swedish Medical Association), CJ van Asperen(Leiden University Medical Center), Konstantinos Tryfonidis(Champalimaud Foundation), Oliver Bögler(National Institutes of Health), Lissandra Dal Lago(Institut Jules Bordet), Coralie Poncet(European Organisation for Research and Treatment of Cancer)
Cited by 396
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial
|Journal of Clinical Oncology|2015|2.6k